Platelet-derived growth factor receptor alpha

Where the papers sit

17 papers from the last 6 months study platelet-derived growth factor receptor alpha directly · updated from PubMed 12 Oct 2026

• Kinase-Targeted Cancer Therapy

  Kinase-directed cancer treatment is moving toward combinations, resensitization, and degradation of oncogenic signaling rather than single-agent inhibition alone. Lenvatinib plus PD-1 blockade benefits gastric cancer through immunosuppressive macrophage modulation, while sorafenib/piroxicam shows biomarker-defined survival in canine urothelial cancer. Wogonin targets PDGFRB in thyroid cancer, and TRIM21-mediated PDGFRA degradation suppresses glioblastoma malignancy. Computational phytochemical and purine-analogue studies extend the search for multi-target apoptosis or autophagy, but clinical validation remains limited.

  6 papers · 35.3%

• PDGFRA-Mutant GIST

  Molecular profiling is driving GIST treatment toward mutation-selected kinase inhibition and resistance management. KIT and PDGFRA alterations anchor large real-world cohorts, while scaffold-hopped inhibitors are designed to overcome mutation-driven resistance. Preoperative avapritinib can produce marked pathologic response in localized PDGFRA-mutant GIST, but standard dosing has limited feasibility. The open question is how genotype, toxicity, and durability should guide sequencing.

  5 papers · 29.4%

• Others — PDGFR-Targeted Fibrosis and Cancer

  PDGFR-directed work here ranges from antifibrotic strategies to tumor imaging and kinase inhibition. miR-149-5p suppresses liver fibrosis by targeting PDGFRB in hepatic stellate cells, while membrane-camouflaged PDGFRA therapy aims to uncouple fibrosis from inflammation. Other studies pursue PDGFRB inhibitors or [68Ga]Ga-ATH001 imaging in hepatocellular carcinoma and angiomyolipoma. A myxoid glioneuronal tumor case does not share this biology, so no unified therapeutic direction emerges.

  6 papers · 35.3%